Skip to Content
  • Previous Rank
    187
  • Revenues ($M)
    $53,647.00
  • Revenue Percent Change
    2.1%
  • Profits ($M)
    $11,153.00
  • Profits Percent Change
    -47.7%
  • Assets ($M)
    $159,422.00
  • Employees
    92,400

In Ian Read’s final year as the company’s CEO, Pfizer managed to grow revenues by just 2% as it adjusted to greater competition to—and diminished sales of—Viagra and other drugs on which the company lost patent exclusivity in 2017. The pharmaceutical giant is now in the midst of a reorganization since announcing in the summer of 2018 that it would separate its business into three parts, one of which (its consumer health division) it plans to merge into a joint venture with GlaxoSmithKline. The moves are designed to position Pfizer for greater sales growth under new CEO Albert Bourla.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

CEO
Albert Bourla
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York City
Websitehttps://www.pfizer.com
Years on Global 500 List25
Employees92,400

Pfizer Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$53,647.002.1%
Profits ($M)$11,153.00-47.7%
Assets ($M)$159,422.00-
Total Stockholder Equity ($M)$63,407.00-

Profit Ratios

Profit as % of Revenues20.8%
Profits as % of Assets7%
Profits as % of Stockholder Equity17.6%